Published September 16, 2019
| Version v1
Dataset
Open
Large-scale purification of Q23 HTT-HAP40 from Sf9 expression system with contaminating nucleic acid material 2019/09/16
Authors/Creators
- 1. Structural Genomics Consortium, University of Toronto
- 2. Structural Genomics Consortium, University of Toronto, MaRS South Tower, 101 College Street, Toronto, Ontario M5G 1L7, Canada and Princess Margaret Cancer Centre and Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G 1L7, Canada
Description
Project: Biophysical investigation of purified HTT protein samples
Experiment: Large-scale purification of Q23 HTT-HAP40 from Sf9 expression system with contaminating nucleic acid material
Date completed: 2019/09/16
Rationale: To purify HTT-HAP40 + Sf9 derived nucleic acid material for cryoEM analysis
Notes
Dr. Harding is the recipient of the Huntington's Disease Society of America Berman Topper Career Development Fellowship which funds and supports this research, in addition to generous funding from the CHDI Foundation and the Huntington Society of Canada. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.